Breaking News

Sotorasib: A New Targeted Therapy for Cancer Treatment

Breaking News:

Sotorasib, a novel targeted therapy drug, has been approved for use in the treatment of certain types of cancer.

Key Points:

* Sotorasib belongs to a group of drugs known as cancer growth inhibitors. * It specifically targets the RAS GTPase family, a protein involved in cell growth and division. * The current price of sotorasib is approximately US$24,000 for a 30-day supply of the 960-mg dose.

Significance:

* Sotorasib represents a significant advancement in cancer treatment, as it offers a precise and targeted approach to combating the disease. * Its approval provides new hope for patients with previously limited treatment options.

Further Updates:

Stay tuned for updates on clinical trials, availability, and ongoing research related to sotorasib and its use in cancer treatment.